T. Rowe Price reports 1.70M shares (3.7%) of Avanos

T. Rowe Price Investment Management, Inc. filed Amendment No. 5 to a Schedule 13G/A reporting beneficial ownership of 1,703,510 shares of Avanos Medical Inc. common stock, representing 3.7% of the class as of 04/30/2026.

Rhea-AI Filing Summary

T. Rowe Price Investment Management, Inc. filed Amendment No. 5 to a Schedule 13G/A reporting beneficial ownership of 1,703,510 shares of Avanos Medical Inc. common stock, representing 3.7% of the class as of 04/30/2026. The filer states it owns 5% or less and disclaims beneficial ownership in the filing.

Insights

Institutional Ownership Analyst

Large institutional holder reports a passive stake of 3.7% in Avanos Medical.

The filing lists 1,703,510 shares and shows 1,680,454 shares of sole voting power and 1,703,510 shares of sole dispositive power as of 04/30/2026. The schedule is consistent with a passive, non-activist ownership disclosure.

Filing includes an explicit statement that the filer does not admit beneficial ownership. Subsequent Form 13D/13G amendments would be required if holdings or intentions materially change.

Key Figures

Beneficially owned shares: 1,703,510 shares Percent of class: 3.7% Sole voting power: 1,680,454 shares +3 more

6 metrics

Beneficially owned shares 1,703,510 shares as of 04/30/2026

Percent of class 3.7% common stock

Sole voting power 1,680,454 shares reported in Item 4(i)

Sole dispositive power 1,703,510 shares reported in Item 4(iii)

Filing amendment Amendment No. 5 Schedule 13G/A

Signature date 05/07/2026 signed by Ellen York, Vice President

Key Terms

Schedule 13G/A, beneficially owned, sole dispositive power, sole voting power

4 terms

Schedule 13G/A regulatory

"Amendment No. 5 to Schedule 13G/A reporting ownership"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

beneficially owned regulatory

"Amount beneficially owned: 1703510"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole dispositive power regulatory

"Sole power to dispose: 1703510"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

sole voting power regulatory

"Sole power to vote: 1680454"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does T. Rowe Price report in AVNS?

T. Rowe Price reports 1,703,510 shares, equal to 3.7% of Avanos Medical's common stock as of 04/30/2026. The filing classifies this as ownership of 5 percent or less of a class.

Does T. Rowe Price claim beneficial ownership of AVNS shares?

No. The filing includes a declaration denying beneficial ownership while still reporting voting and dispositive powers for 1,703,510 shares. This language is a legal disclosure and does not change the reported share counts.

What voting and dispositive powers are reported in the 13G/A?

The filer reports 1,680,454 shares with sole voting power and 1,703,510 shares with sole dispositive power. Shared voting and dispositive powers are reported as 0 in the filing.

What does 'Amendment No. 5' indicate for this Schedule 13G/A?

It indicates this is the fifth amendment to an earlier Schedule 13G filing for the same holding. Amendments update ownership details; here they reconcile reported share counts and the filer’s disclosure as of 04/30/2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/07/2026 - 11:03 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 5)

AVANOS MEDICAL INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

05350V106

(CUSIP Number)

04/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 05350V106

1

Names of Reporting Persons

T. Rowe Price Investment Management, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MARYLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,680,454.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,703,510.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,703,510.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.7 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: AVANOS MEDICAL INC
(b)	Address of issuer's principal executive offices: 5405 WINDWARD PARKWAY, SUITE 100 SOUTH, ALPHARETTA, GA, 30004
Item 2.
(a)	Name of person filing: T. Rowe Price Investment Management, Inc.
(b)	Address or principal business office or, if none, residence: 1307 Point Street, Baltimore, MD 21231
(c)	Citizenship: Maryland
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: 05350V106
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 1703510
(b)	Percent of class: 3.7 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 1680454
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 1703510
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

T. Rowe Price Investment Management, Inc.

Signature:	Ellen York
Name/Title:	Vice President
Date:	05/07/2026